BUSINESS

Biogen to Leverage Aducanumab Learnings, Spinraza to Remain Foundation of SMA Care: Japan Chief

June 3, 2019
Despite the aducanumab flop earlier this year and the arrival of a one-time competitor treatment in the spinal muscular atrophy (SMA) space, Biogen Japan helmsman Ajai Sulekh stresses the big biotech’s unwavering commitment to Alzheimer’s drug development and its confidence…

To read the full story

Related Article

BUSINESS

By Ludwig Kanzler

As reported previously, Reed Maurer passed away on August 30 due to complications from pneumonia. He was approaching his 84th birthday.Reed has been a driver of the international pharma community in Japan like nobody else. Arriving over fifty years ago…

By Takashi Ohama

Over two years after the rollout of the cost-effectiveness assessment (CEA) scheme in April 2019, discussions on its system reform are set to go into full swing at a key reimbursement policy council known as Chuikyo. Both payer and healthcare…

The average ratio of female employees at managerial posts stood at just 12.5% at pharmaceutical companies operating in Japan, a Jiho survey revealed. While foreign drug makers had an average 25.0%, the ratio came to as low as 9.8% for…

By Yoshinori Sagehashi

Biogen’s controversial Alzheimer’s drug aducanumab was filed for Japanese regulatory approval in December. If approved, it will be the first…

Japan’s key reimbursement policy panel on December 20 approved an outline of its FY2020 drug pricing reform next April, with…

Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…